Background:
Palmar-plantar atopic dermatitis is a common and debilitating condition with significant diagnostic and management challenges.
Case presentation:
The paper presents the successful treatment of dupilumab in five female patients with recalcitrant palmar-plantar atopic dermatitis.
Methods:
The Hand Eczema Severity Index (HECSI) and the Foot Eczema Severity Index (FECSI), eosinophils and IgE levels were evaluated before and after the treatment.
Results:
Five recalcitrant palmar-plantar atopic dermatitis patients had substantial responses to dupilumab and the persistent pruritus was soon alleviated during the therapy. By week 16, all patients' palmar-plantar eczema has been almost clear, with significant decrease of HECSI and FECSI. The count of eosinophils and IgE levels returned to normal in all patients.
Conclusion:
Dupilumab significantly improves disease severity and reduces eosinophils and IgE in refractory palmar-plantar AD patients.